|Articles|September 12, 2012

Patient Possibilities footer references

References 1. FASLODEX [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2010. 2. Di Leo A, Jerusalem G, Petruzelka L, et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg
with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.
[published errata appears in J Clin Oncol. 2011;29(16):2293] J Clin Oncol. 2010;28(30):4594-4600. 3. Data on File, 1137103. AstraZeneca Pharmaceuticals LP, Wilmington, DE. 4. Data on File, 1196503. AstraZeneca Pharmaceuticals LP, Wilmington, DE. 5. Data on File, 1390903. AstraZeneca Pharmaceuticals LP, Wilmington, DE. 6. Data on File, 1373902. AstraZeneca Pharmaceuticals LP, Wilmington, DE.

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Related to this article

Bhanu Prasad Venkatesulu, MBBS, MD, discussed why fewer radiation oncologists offer prostate brachytherapy and the patients for whom he still recommends it.

November 5th, 2026

Where Does Prostate Brachytherapy Fit Best in the Treatment Paradigm?

Bhanu Prasad Venkatesulu, MBBS, MD, discussed why fewer radiation oncologists offer prostate brachytherapy and the patients for whom he still recommends it.

Chinmay Jani, MD, explains how air pollution and asbestos contribute to lung cancer deaths beyond tobacco.

November 5th, 2026

Air Pollution Emerges as Second Leading Risk Factor for Lung Cancer Deaths

Chinmay Jani, MD, explains how air pollution and asbestos contribute to lung cancer deaths beyond tobacco.

November 5th, 2026

Sacituzumab Govitecan Efficacy, Safety Debated in First-Line Metastatic TNBC

Claudine Isaacs, MD, and community oncologists weigh ASCENT-03 and ASCENT-04 data, crossover, and toxicity management with sacituzumab govitecan in TNBC.

November 5th, 2026

FDA Sets PDUFA Date for Rivoceranib/Camrelizumab Resubmission After Third CRL in Unresectable HCC

The FDA assigned an April 9, 2027, target action date to resubmitted applications for rivoceranib plus camrelizumab in unresectable or metastatic hepatocellular carcinoma.

November 5th, 2026

Evaluating Factors That Affect HDR Brachytherapy and SBRT Decisions in Radiation Oncology

Adam C. Olson, MD, MSc-GH, discussed letting patients choose between modalities with comparably strong evidence, and the data that shaped his approach.